These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 32515665)

  • 41. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
    Fleischmann RM; Blanco R; Hall S; Thomson GTD; Van den Bosch FE; Zerbini C; Bessette L; Enejosa J; Li Y; Song Y; DeMasi R; Song IH
    Ann Rheum Dis; 2021 Apr; 80(4):432-439. PubMed ID: 33148701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
    Reddy V; Cohen S
    Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
    Deodhar A; van der Heijde D; Sieper J; Van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Ostor A; Combe B; Sui Y; Chu AD; Song IH
    Arthritis Rheumatol; 2022 Jan; 74(1):70-80. PubMed ID: 34196498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
    Mysler E; Lizarraga A
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
    Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Placebo Response in Rheumatoid Arthritis Clinical Trials.
    Bechman K; Yates M; Norton S; Cope AP; Galloway JB
    J Rheumatol; 2020 Jan; 47(1):28-34. PubMed ID: 31043548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upadacitinib for the treatment of adult patients with active psoriatic arthritis.
    Marchesoni A; Citriniti G; Girolimetto N; Possemato N; Salvarani C
    Expert Rev Clin Immunol; 2024 May; 20(5):423-434. PubMed ID: 38155531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.
    Witte T; Kiltz U; Haas F; Riechers E; Prothmann U; Adolf D; Holland C; Rössler A; Soppa U; Fritz B; Götz K; Krüger K;
    Clin Exp Rheumatol; 2024 Mar; 42(3):726-735. PubMed ID: 37976112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upadacitinib: First Approval.
    Duggan S; Keam SJ
    Drugs; 2019 Nov; 79(16):1819-1828. PubMed ID: 31642025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 55. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
    Fleischmann R
    Expert Opin Pharmacother; 2017 Oct; 18(14):1525-1533. PubMed ID: 28829236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
    Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
    Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
    Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
    Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.